Received: from nobody by stodi.digitalkingdom.org with local (Exim 4.91) (envelope-from ) id 1g9ZyE-0002w9-FV for lojban-newreal@lojban.org; Mon, 08 Oct 2018 11:09:30 -0700 Received: from [192.3.13.199] (port=26068 helo=forltor.club) by stodi.digitalkingdom.org with esmtp (Exim 4.91) (envelope-from ) id 1g9ZyB-0002vB-V0 for lojban@lojban.org; Mon, 08 Oct 2018 11:09:30 -0700 From: " Marty Schmidt" Date: Mon, 08 Oct 2018 13:01:21 -0500 MIME-Version: 1.0 Subject: Professional hi-end 3D creation program... To: Message-ID: Content-Type: multipart/alternative; boundary="------------06461638489459292305926" X-Spam-Score: 3.4 (+++) X-Spam_score: 3.4 X-Spam_score_int: 34 X-Spam_bar: +++ X-Spam-Report: Spam detection software, running on the system "stodi.digitalkingdom.org", has NOT identified this incoming email as spam. The original message has been attached to this so you can view it or label similar future email. If you have any questions, see the administrator of that system for details. Content preview: I just came across this incredible animation software which you shouldcheck out immediately . It's a really easy but an effective software tocreate 3d animations, models, games, graphics andmuch more .Cool thing is, I've been quietly using testing IllusionMage for the past 5 months andI've created 3 short cartoon films and countless of 3d models. Nothing in the market comes close to the value and offering this animation software package offers. At the price Seth is offering, he'll be crazy if he keeps it up.Go now as this offer comes down in the next few days (time sensitive).Take action on this before it's gone as opportunity seldom knock twice.Warmly,Dennis PerezP.S: Take alook at the videos on the site to see how YOU can create powerful 3d animations like Pixar and Dreamworks. If you'd prefer not to receive future emails,Unsubscribe Here. 2329 Whispering Pines Circle Allen, TX 75002 Existing Drug Shows Promise in Treating Heart Failure Researchers say the drug tafamidis has shown in clinical trials that it can lessen the effects of a heart condition known as ATTR-CM.Theres a form of heart failure that may be more common than thought. And theres no treatment for it.But an existing drug just passed a critical step and may soon be approved to treat this overlooked condition.On average, people three to five years after getting a diagnosis of transthyretin amyloid cardiomyopathy, or ATTR-CM.Its a rare disease in which certain proteins gradually build up in the tissues of the heart, eventually making it more difficult for the heart to pump blood to the rest of the body.It can eventually lead to heart failure.However, in a clinical trial whose results were published last week, a drug called tafamidis lessened some of the worst effects of ATTR-CM.Researchers reported that the chance of death was reduced by 30 percent, heart-related hospitalizations were reduced by 32 percent, and declines in quality of life were slowed for people who received the drug versus those who received a placebo.This is a fascinating set of discoveries, really is breakthrough science, Dr. Clyde Yancy, chief of cardiology at Northwestern Universitys Feinberg School of Medicine in Chicago, told Healthline. The impact on patients is uncertain because this isnt a terribly common condition, but it is a condition of great consequences.The most important thing, Yancy says, is that its a step forward toward treating a condition that had been considered untreatable.Even though the scope is a small number of patients at present, it could reach a large number of patients down the road, he said.What is ATTR-CM?A 2017 estimate put the percentage of people in the United States who have ATTR-CM at 0.001 percent. The percentage is slightly higher among men over age 60.With this disease, a protein called transthyretin unravels, travels to the heart, and clumps together there in deposits. --------------06461638489459292305926 Content-Type: text/html; charset=ISO-8859-1 Content-Transfer-Encoding: 7bit

 

illusion_Mage
I just came across this incredible animation software which you should check out immediately.



It's a really easy but an effective software to create 3d animations, models, games, graphics and much more.

Cool thing is, I've been quietly using testing IllusionMage for the past 5 months and I've created 3 short cartoon films and countless of 3d models. Nothing in the market comes close to the value and offering this animation software package offers. At the price Seth is offering, he'll be crazy if he keeps it up.

Go now as this offer comes down in the next few days (time sensitive).

Take action on this before it's gone as opportunity seldom knock twice.

Warmly,
Dennis Perez

P.S: Take a look at the videos on the site to see how YOU can create powerful 3d animations like Pixar and Dreamworks.

 

 

 

 


 

 

 

 

If you'd prefer not to receive future emails, Unsubscribe Here.
2329 Whispering Pines Circle Allen, TX 75002

Existing Drug Shows Promise in Treating Heart Failure Researchers say the drug tafamidis has shown in clinical trials that it can lessen the effects of a heart condition known as ATTR-CM.There’s a form of heart failure that may be more common than thought. And there’s no treatment for it.But an existing drug just passed a critical step and may soon be approved to treat this overlooked condition.On average, people three to five years after getting a diagnosis of transthyretin amyloid cardiomyopathy, or ATTR-CM.It’s a rare disease in which certain proteins gradually build up in the tissues of the heart, eventually making it more difficult for the heart to pump blood to the rest of the body.It can eventually lead to heart failure.However, in a clinical trial whose results were published last week, a drug called tafamidis lessened some of the worst effects of ATTR-CM.Researchers reported that the chance of death was reduced by 30 percent, heart-related hospitalizations were reduced by 32 percent, and declines in quality of life were slowed for people who received the drug versus those who received a placebo.“This is a fascinating set of discoveries, really is breakthrough science,” Dr. Clyde Yancy, chief of cardiology at Northwestern University’s Feinberg School of Medicine in Chicago, told Healthline. “The impact on patients is uncertain because this isn’t a terribly common condition, but it is a condition of great consequences.”The most important thing, Yancy says, is that it’s a step forward toward treating a condition that had been considered untreatable.“Even though the scope is a small number of patients at present, it could reach a large number of patients down the road,” he said.What is ATTR-CM?A 2017 estimate put the percentage of people in the United States who have ATTR-CM at 0.001 percent. The percentage is slightly higher among men over age 60.With this disease, a protein called transthyretin unravels, travels to the heart, and clumps together there in deposits.






 
--------------06461638489459292305926--